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Abstract  
The cis-α isomer of [Ru(bb7)(dppz)]
2+ 
{dppz = dipyrido[3,2-a:2′,3′-c]phenazine; bb7 = 
bis[4(4'-methyl-2,2'-bipyridyl)]-1,7-alkane} has been synthesised.  The minimum inhibitory 
concentrations and the minimum bactericidal concentrations of [Ru(bb7)(dppz)]
2+
 and its 
parent complex [Ru(phen)2(dppz)]
2+
 (phen = 1,10-phenanthroline) were determined against a 
range of bacteria.  The results showed that both ruthenium complexes exhibited good activity 
against Gram-positive bacteria, but [Ru(bb7)(dppz)]
2+
 showed at least eight-times better 
activity across the Gram-negative bacteria than [Ru(phen)2(dppz)]
2+
.  Luminescence assays 
demonstrated that [Ru(bb7)(dppz)]
2+
 accumulated in a Gram-negative bacterium to the same 
degree as in a Gram-positive species, while assays with liposomes showed that 
[Ru(bb7)(dppz)]
2+
 interacted more strongly with membranes compared to the parent 
[Ru(phen)2(dppz)]
2+
 complex.  The DNA binding affinity for [Ru(bb7)(dppz)]
2+
 was 
determined to be 6.7 × 10
6
 M
-1
.  Although more toxic to eukaryotic cells than 
[Ru(phen)2(dppz)]
2+
, [Ru(bb7)(dppz)]
2+
 exhibited greater activity against bacteria than 
eukaryotic cells.     
 
Introduction 
There has been recent interest in developing kinetically-inert polypyridylruthenium(II) 
complexes as therapeutic agents,
[1-5] 
with complexes containing the dipyrido[3,2-a:2′,3′-
c]phenazine (dppz) ligand attracting particular attention.
[6-8]  
Barton and co-workers 
established that [Ru(bpy)2(dppz)]
2+
 (bpy = 2,2'-bipyridine) and [Ru(phen)2(dppz)]
2+
 (phen = 
1,10-phenanthroline) strongly bind DNA by intercalation, and because these complexes 
exhibit negligible background emission in aqueous solution but display strong luminescence 
upon DNA binding, they are now known as Òmolecular light-switchesÓ.
[9,10]
  The dppz 
complexes have subsequently been utilised in numerous biological studies; for example, as 
DNA and cellular imaging agents, nuclear acid-based sensors and as potential therapeutic 
drugs.
[6-8,11-13]
 
 
Although [Ru(bpy)2(dppz)]
2+
 and [Ru(phen)2(dppz)]
2+
 bind DNA strongly, they have 
generally exhibited low cytotoxicity against eukaryotic cells, with a number of studies 
indicating that the low cytotoxicity was due to their poor cellular uptake.
[14-16]  
Puckett and 
Barton demonstrated that these complexes enter eukaryotic cells by passive diffusion, and that 
the uptake can be enhanced by increasing the lipophilicity of the complex, e.g. by substituting 
the bpy or phen ligands with 4,7-diphenyl-1,10-phenanthroline (DIP).
[14]
  Similarly, a number 
of more recent studies have also demonstrated that dppz-based complexes which are more 
lipophilic than [Ru(phen)2(dppz)]
2+
 exhibit good activity against a range of cancer cell lines: 
e.g. [Ru(dppz)2(CppH)]
2+
 {CppH = 2-(2'-pyridyl)pyrimidine-4-carboxylic acid}
[17,18]
 and 
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[Ru(bpy)(phpy)(dppz)]
+
 (phpy = 2-phenylpyridine).
[19]
  
 
Given the greater presence of negatively-charged components (phospholipids, such as 
phosphatidyl-glycerol, teichoic acids and lipopolysaccharides) in the bacterial membrane and 
cell wall compared to eukaryotic membranes,
[20]
 it could be anticipated that 
[Ru(phen)2(dppz)]
2+
 would show good antimicrobial activity.  Consistent with this proposal, 
Aldrich-Wright and co-workers found that [Ru(2,9-Me2phen)2(dppz)]
2+
 (2,9-Me2phen = 2,9-
dimethyl-1,10-phenanthroline) displayed good activity against Gram-positive bacteria − even 
drug-resistant strains.
[21]
  However, and consistent with other studies, the dppz-based 
ruthenium complex showed no activity against Gram-negative bacteria.  As Gram-negative 
bacteria have two membrane layers rather than the single cytoplasmic membrane present in 
Gram-positive species, the poor activity is again due to the lack of cellular uptake. 
 
In order to increase the antimicrobial activity of [Ru(2,9-Me2phen)2(dppz)]
2+
, the 2,9-
Me2phen ligands could be replaced with a more lipophilic ligand such as DIP.  However, this 
would also significantly increase the toxicity of the ruthenium complex to eukaryotic 
systems.
[15-17]
  In addition, a number of studies have also demonstrated that the cellular 
localisation of polypyridylruthenium(II) complexes in eukaryotic cells is significantly 
modulated by the lipophilicity.
[22]
  Consequently, it could be beneficial to increase the uptake 
into bacterial cells through another mechanism that does not require an increase in the 
lipophilicity.  In a recent solid-state NMR and molecular dynamics study of the interaction of 
the dinuclear complex [{Ru(phen)2}2(µ-bb12)]
4+
 {where bb12 = bis[4(4'-methyl-2,2'-
bipyridyl)]-1,12-dodecane} with model membranes it was shown that the two metal centres 
could be embedded at the level of the membrane phosphate group with the alkyl linker dipped 
into the hydrophobic interior of the membrane.
[23]
  As an alternative approach to utilising 
dinuclear complexes, the alkyl chain could be incorporated into a mononuclear complex 
through an additional chelate ring involving the polymethylene chain in a tetradendate bbn 
ligand (where n = the number of carbons in the chain), as shown in Figure 1.  We have 
previously synthesised [Ru(phen')(bb7)]
2+
 (where phen' = phen and its 5-nitro-, 4,7-dimethyl- 
and 3,4,7,8-tetramethyl- derivatives) complexes and examined their antimicrobial activities.
[24]
  
As the log P (a measure of lipophilicity) values for the [Ru(phen')(bb7)]
2+
 complexes (-1.33 to 
-1.83) were approximately the same as that reported for [Ru(phen)2(dppz)]
2+
 (-1.48),
[14]
 we 
sought to synthesise [Ru(bb7)(dppz)]
2+
 (see Figure 1) and examine its antimicrobial activity 
against a range of bacteria, including a number of Gram-negative species. 
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Figure 1. [Ru(phen)2(dppz)]
2+
(left) and [Ru(bb7)(dppz)]
2+
 (right) 
 
Herein, we describe the synthesis of  [Ru(bb7)(dppz)]
2+ 
and an analysis of its log P, DNA 
binding and antimicrobial activities compared to [Ru(phen)2(dppz)]
2+
.  The results 
demonstrate that [Ru(bb7)(dppz)]
2+
 binds DNA with a slightly higher affinity than 
[Ru(phen)2(dppz)]
2+
, and despite having a very similar log P value, shows significantly 
greater activity against Gram-negative bacteria.  Furthermore, experiments with liposomes 
indicate that [Ru(bb7)(dppz)]
2+
 interacts differently with membranes than [Ru(phen)2(dppz)]
2+
, 
while cellular uptake experiments suggest that [Ru(bb7)(dppz)]
2+
 does readily accumulate in 
Gram-negative bacteria. 
 
Results  
Synthesis and characterisation 
The synthesis of the [Ru(bb7)(dppz)]
2+
 complex containing the flexible bb7 ligand is presented 
in Scheme 1.  In order to avoid the formation of the dinuclear complex, the [Ru(bb7)(dppz)]
2+
 
was synthesised by direct reaction of bb7 with the appropriate mole ratio of the precursor 
complex cis,cis-[RuCl2(DMSO)2(dppz)] in ethylene glycol as previously reported.
[25]
  The 
[Ru(bb7)(dppz)]
2+
 complex was purified by SP Sephadex C-25 cation-exchange 
chromatography.  Only the cis-α isomer of [Ru(bb7)(dppz)]
2+
 was obtained, consistent with 
what was reported for the [Ru(phen')(bb7]
2+
 complexes.
[24]
  The [Ru(bb7)(dppz)]
2+
 complex 
was characterised by microanalysis, NMR spectroscopy and high-resolution electrospray 
ionisation (ESI) mass spectrometry.  The [Ru(bb7)(dppz)]
2+
 complex displayed  a resolvable 
1
H NMR spectrum, and all proton chemical shifts were assigned based on the comparison 
with those of similar compounds.
[25,26]
  Only one symmetrical set of resonances was observed 
for both the dppz and bb7 aromatic protons.  
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Scheme 1 Synthesis of [Ru(bb7)(dppz)]
2+
 
 
Lipophilicity (log P) 
Lipophilicity is an important factor in the cellular uptake of a compound, particularly for 
[Ru(N-N)2(dppz)]
2+
 complexes (where N-N = a bidentate polypyridyl ligand such as bpy, 
phen, DIP, etc.) that enter cells via passive diffusion.
[14,27]
  For example, [Ru(DIP)2(dppz)]
2+
 
(log P = +1.30)
 [14]
 can easily enter cells, whereas, [Ru(phen)2(dppz)]
2+
 (log P = -1.48) cannot.  
The octanol/water partition coefficients (log P) of [Ru(phen)2(dppz)]
2+
 and [Ru(bb7)(dppz)]
2+
, 
as chloride salts, were measured in water.  In agreement with previous studies,
[14]
 the log P of 
[Ru(phen)2(dppz)]
2+
 was determined to be -1.45, while a value of -1.35 was obtained for 
[Ru(bb7)(dppz)]
2+
.  
 
Antimicrobial activity  
The minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations 
(MBC) for [Ru(bb7)(dppz)]
2+
 and [Ru(phen)2(dppz)]
2+
 against six bacterial strains − a 
methicillin-resistant Staphylococcus aureus (MRSA) and a methicillin-sensitive strain of S. 
aureus; two avian pathogenic (APEC) and uropathogenic (UPEC) strains of Escherichia coli 
and a laboratory strain (E. coli MG1655); and Pseudomonas aeruginosa (PAO1) − were 
determined, and the results are summarised in Tables 1 and 2.  For comparison, the MIC and 
MBC values for a selection of antibacterial drugs in clinical use, and included on the WHO 
list of essential medicines, are also presented.  As expected, [Ru(phen)2(dppz)]
2+
 showed 
good activity against the Gram-positive bacteria, but poor (64 µg/ml) or no activity (> 128 
µg/ml) against the Gram-negative species.  Alternatively, [Ru(bb7)(dppz)]
2+
 displayed good 
activity against both Gram-positive and Gram-negative bacteria.  Against the Gram-positive 
species, [Ru(bb7)(dppz)]
2+
 displayed similar activity to [Ru(phen)2(dppz)]
2+
, but was at least 
eight-fold more active against the Gram-negative species.  Furthermore, as the MBC values 
are ≤ double the MIC values, it can be concluded that [Ru(bb7)(dppz)]
2+
 is bactericidal to both 
Gram-positive and Gram-negative species.  In order to assess the importance of the dppz 
ligand in [Ru(bb7)(dppz)]
2+
, the MIC and MBC values were compared to those previously 
determined for [Ru(bb7)(Me2phen)2]
2+
 (Me2phen = 4,7-dimethyl-1,10-phenanthroline) which 
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has a similar log P value (-1.41)
[24]
 to [Ru(bb7)(dppz)]
2+
 and [Ru(phen)2(dppz)]
2+
.  
Interestingly, [Ru(bb7)(Me2phen)2]
2+
 also showed poor activity against the Gram-negative 
species, suggesting that the dppz ligand is an important aspect of the antimicrobial 
mechanism of action.  As inert polypyridylruthenium(II) complexes have been shown to bind 
DNA and RNA in live bacteria and eukaryotic cells,
[28,29]
 the increased activity of 
[Ru(bb7)(dppz)]
2+
, compared to [Ru(bb7)(Me2phen)2]
2+
, is most likely due to the ability of the 
dppz ligand to bind nucleic acids by intercalation.  Although [Ru(bb7)(dppz)]
2+
 exhibited 
lower activity against Gram-negative bacteria than gentamicin, its activity profile is similar to 
that of doxycycline, an antibacterial agent used against a variety of Gram-negative species 
including E. coli.
[30]
 
 
Table 1. MIC values (µg/mL) for the ruthenium complexes and a selection of clinically 
used antibacterial agents against Gram-positive and Gram-negative bacterial 
strains. 
 Gram-positive  Gram-negative 
Compound S. 
aureus 
MRSA  MG1655 APEC UPEC PAO1 
[Ru(bb7)(dppz)]
2+
 2 2  8 8 8 16 
[Ru(phen)2(dppz)]
2+
 4 2  64 64 64 >128 
#
[Ru(bb7)(Me2phen)]
2+
 8 8  32 64 128 >128 
        
Gentamicin 0.25 0.25  0.5 0.5 1 0.25 
Ampicillin 0.5 4  >128 >128 >128 >128 
Doxycyline 4 0.13  16 8 16 32 
Ciprofloxacin 1 2  64 64 64 0.5 
Vancomycin 0.5 0.5  >128 >128 64 >128 
#
Data for [Ru(bb7)(Me2phen)]
2+
 taken from reference 24 
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Table 2. MBC values (µg/mL) for the ruthenium complexes and a selection of clinically 
used antibacterial agents against Gram-positive and Gram-negative bacterial 
strains. 
 Gram-positive  Gram-negative 
Compound S. aureus MRSA 
 
MG1655 APEC UPEC PAO1 
[Ru(bb7)(dppz)]
2+
 4 4  8 16 16 32 
[Ru(phen)2(dppz)]
2+
 8-16 8  64 64 >128 >128 
#
[Ru(bb7)(Me2phen)]
2+
 64 16  ≥128 ≥128 >128 >128 
        
Gentamicin 2 1  2 1 4 1 
Ampicillin 1 4  >128 >128 >128 >128 
Doxycyline 1 0.25  32 64 128 32 
Ciprofloxacin 2 4  >128 >128 >128 1 
Vancomycin 0.5 2  >128 >128 >128 >128 
#
Data for [Ru(bb7)(Me2phen)]
2+
 taken from reference 24 
 
 
Cellular accumulation 
 As [Ru(bb7)(dppz)]
2+
 showed good antimicrobial activity against both Gram-positive and 
Gram-negative bacteria, it was of interest to compare the cellular accumulation of the 
ruthenium complex in Gram-positive MRSA and Gram-negative P. aeruginosa (PAO1). 
Although the outer membrane limits the uptake of drugs into the cell for all Gram-negative 
bacteria, it is particularly significant for P. aeruginosa,
[31,32]
 which is known to be resistant to 
many antimicrobials due to the low permeability of its outer membrane.  As shown in Figure 
2, the cellular accumulation of [Ru(bb7)(dppz)]
2+
 in MRSA and PAO1 are approximately 
equal, suggesting that [Ru(bb7)(dppz)]
2+
 can be readily taken up by both Gram-positive and 
Gram-negative bacteria. 
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Figure 2. Cellular accumulation of [Ru(bb7)(dppz)]
2+
 into the Gram-positive bacterium 
MRSA and Gram-negative PAO1 after incubation for 15, 30, 60, 90 and 120 
minutes. 
 
Liposome membrane permeability 
As the cellular accumulation experiments indicated that [Ru(bb7)(dppz)]
2+
 was readily taken 
up by both Gram-positive and Gram-negative bacteria, its interaction with a model membrane 
system using carboxyfluorescein-filled 1,2-dioleoylphosphatidylglycerol (DOPG) liposomes 
was examined.  Carboxyfluorescein is a membrane-impermeant fluorescent dye (λex = 495 nm 
and λem = 517 nm) that is commonly used in liposomes to examine the effect of potential 
drugs on membranes.
[33]
  Control experiments with colistin, a cationic polypeptide antibiotic 
known to permeabilise bacterial membranes,
[34]
 confirmed the partial release of 
carboxyfluorescein from the liposomes (see Figure 3), with the remainder of the dye released 
upon the subsequent addition of Triton-X (a detergent that lyses cells).  Upon addition of 
[Ru(phen2)(dppz)]
2+
, the dye release profile was similar to that of colistin (see Figure 3), 
suggesting that it did have an effect on the permeability of the DOPG liposomes.  However, 
the effect with [Ru(bb7)(dppz)]
2+
 was much stronger, with all the dye being released very 
rapidly.  Although only a model membrane system, the carboxyfluorescein-filled DOPG 
liposome experiments suggests [Ru(bb7)(dppz)]
2+
 has a much stronger effect on membranes 
than [Ru(phen2)(dppz)]
2+
. 
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Figure 3. The effect of [Ru(phen2)(dppz)]
2+
and [Ru(bb7)(dppz)]
2+
 on DOPG liposomes 
at 1 µg/mL ruthenium complex concentration.  Control (colistin, red curve) 
and ruthenium complex (black curve). 
 
DNA binding 
The affinities of the [Ru(phen)2(dppz)]
2+
and [Ru(bb7)(dppz)]
2+
complexes with CT-DNA were 
determined by UV-visible absorption spectral studies in PBS buffer at room temperature.  The 
absorption spectra of the two complexes in the presence and absence of CT-DNA ([Ru] = 20 
µM) are shown in Figure 4.  In the visible region, the broad bands at the lowest energy at 439 
nm for [Ru(phen)2(dppz)]
2+
 and [Ru(bb7)(dppz)]
 2+
 are attributed to the metal-to-ligand charge 
transfer (MLCT) transition.  With increasing DNA concentration, the hypochromism in the 
MLCT band was 12.3% at a ratio of [DNA]/[Ru] = 2.0 for [Ru(phen)2(dppz)]
2+
 and 10.1% at 
a ratio of [DNA]/[Ru] = 2.2 for [Ru(bb7)(dppz)]
2+
.   The intrinsic binding constants K were 
obtained according to eq.1, and the values determined for [Ru(phen)2(dppz)]
2+
 and 
[Ru(bb7)(dppz)]
2+
 were 2. 6 × 10
6 
M
-1
 and 6.7 × 10
6
 M
-1
, respectively.  The binding constant 
determined for [Ru(phen)2(dppz)]
2+
 is consistent with previously reported values by others 
(5.1 × 10
6
 M
-1
).
[35]
  From the results obtained, it is clear that the DNA binding affinity of 
[Ru(bb7)(dppz)]
2+
 is at least equivalent to the parent [Ru(phen)2(dppz)]
2+
 complex.  
Furthermore, based upon the significant hypochromic shift observed in the MLCT band at 
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439 nm, it can be concluded that [Ru(bb7)(dppz)]
2+
 binds DNA by intercalation.  As has been 
demonstrated in many previous studies, the DNA binding constant will be affected to some 
degree by the nature of the ancillary ligands; consequently, it is not surprising that there is a 
small difference in affinity between the two dppz-based ruthenium complexes. 
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Figure 4. Absorption spectra of the ruthenium complexes [Ru(phen)2(dppz)]
2+
 (top) and  
[Ru(bb7)(dppz)]
2+
 (bottom) in buffer and upon the addition of CT-DNA, [Ru] 
= 20 µM, [DNA] = 0 − 50 µM.  Arrow shows the absorbance changing upon 
the increase in DNA concentration. Inset: plots of (εa−εf )/(εb−εf ) vs. [DNA] 
for the titration of DNA to Ru(II) complexes. 
 
Toxicity to eukaryotic cells 
To further evaluate the potential of [Ru(bb7)(dppz)]
2+
 as an antimicrobial agent, an 
understanding of its cytotoxicity towards mammalian cells is necessary.  The cytotoxicities of 
[Ru(phen)2(dppz)]
2+
 and  [Ru(bb7)(dppz)]
2+
 against several eukaryotic cell lines over a 48 
hour time-frame were determined, and the results are shown in Table 3.  The results indicate 
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that [Ru(bb7)(dppz)]
2+
 is more toxic than [Ru(phen)2(dppz)]
2+
 to eukaryotic cells, particularly 
the HepG2 cancer cell line.  However, comparing the IC50 data to the MIC data (1 µM  = 0.9 
µg/mL), it is noted that  [Ru(bb7)(dppz)]
2+
 is nevertheless more toxic to the bacteria than to 
the healthy cell lines HEK-293 and L02. 
 
 
Table 3.  48h-IC50 values (µM) of the ruthenium complexes against the eukaryotic cell 
lines ACHN (kidney cancer cell), HEK-293 (healthy kidney cell), HepG2 
(liver cancer cell) and L02 (healthy liver cell).  
 ACHN HEK-293 HepG2 L02 
[Ru(phen)2(dppz)]
2+
 102.9 ± 30.7 103.3 ± 14.1  61.7 ± 11.1 > 200 
[Ru(bb7)(dppz)]
2+
 22.8 ± 1.1 29.5 ± 2.6 4.9 ± 0.4 71.4 ± 4.3 
Cisplatin 2.9 ± 0.1 37.9 ± 5.9  7.4 ± 1.0 14.6 ± 2.0 
 
 
Discussion 
Recently, the WHO published a ÒGlobal priority list of antibiotic-resistant bacteria to guide 
research, discovery and development of new antibioticsÓ.
[36]
  The published priority list was 
divided into three categories: critical; high; and medium.  All the bacteria in the critical class 
were Gram-negative species, and included P. aeruginosa and enterobacteriaceae species 
(which includes E. coli).  There is clearly a need for the development of new classes of 
antimicrobial agents, and kinetically-inert polypyridylruthenium(II) complexes have shown 
considerable potential in this regard.
[3,4]
  A variety of compounds from this class of ruthenium 
complexes have shown good antimicrobial activities, and recently several have shown good 
antiparasitic activity in in vivo studies.
[37]
  However, to date, the much-studied class that 
contains the dppz ligand has only shown significant activity against Gram-positive bacterial 
strains.
[21]
  In this study, we have shown that incorporating the bb7 tetradentate ligand into the 
Ru(dppz) scaffold results in a complex that is active against Gram-negative bacteria, but 
without increasing the lipophilicity of the complex compared to the parent 
[Ru(phen)2(dppz)]
2+
.   
 
In addition to the differences in antimicrobial activities between the [Ru(phen)2(dppz)]
2+
 and 
[Ru(bb7)(dppz)]
2+
, some other interesting differences were observed in the activity profile of 
[Ru(bb7)(dppz)]
2+
 compared to the previously-reported [Ru(phen')(bb7)]
2+
 complexes.  
Although [Ru(bb7)(Me2phen)]
2+
 has an almost identical log P value to [Ru(bb7)(dppz)]
2+
, it 
was much less active than the dppz-based complex to Gram-negative species.  This suggests 
the dppz ligand plays a specific role in the mechanism of antimicrobial activity, and given its 
well-known role in DNA binding,
[9,10]
 it is likely that [Ru(bb7)(dppz)]
2+
 inhibits bacterial 
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transcription and/or translation processes.  DNA binding experiments demonstrated that 
[Ru(bb7)(dppz)]
2+
 bound CT-DNA slightly more strongly than [Ru(phen)2(dppz)]
2+
.  
Furthermore, [Ru(bb7)(dppz)]
2+
 exhibited slightly better activity than the more lipophilic 
[Ru(bb7)(Me4phen)]
2+
; surprisingly, [Ru(bb7)(dppz)]
2+
 was determined to be bactericidal, 
while [Ru(bb7)(Me4phen)]
2+
 (Me4phen = 3,4,7,8-tetramethyl-1,10-phenanthroline) was 
bacteriostatic with very high MBC values (> 128 µg/mL) against UPEC and PAO1.
[24]
 
 
It is yet to be determined why [Ru(bb7)(dppz)]
2+
 displays better activity to Gram-negative 
bacteria compared to [Ru(phen)2(dppz)]
2+
; however, the results from the DOPG liposome 
experiments clearly indicate that [Ru(bb7)(dppz)]
2+
 has a greater effect on membrane stability 
compared to the parent complex.  Similar carboxyfluorescein release profiles were observed 
for [Ru(phen)2(dppz)]
2+
 and colistin. The polymyxin colistin initially binds by electrostatic 
interaction between the positively-charged antibiotic and the negatively-charged phosphate 
group of lipid A on lipopolysaccharide (LPS) localised on the outer leaflet of the bacterial 
outer membrane.
[34]
  Following its diffusion from the outer membrane across the periplasm, 
the polymyxin intercalates into the inner membrane and forms pores, which in turn results in 
bacterial lysis.  While DOPG liposomes are only a very approximate model of a Gram-
negative membrane, it is possible that the ruthenium complexes could also displace Ca
2+
 and 
Mg
2+
 ions from the phosphate groups.  Furthermore, as the effect on the DOPG liposomes 
was significantly stronger and more complete upon addition of [Ru(bb7)(dppz)]
2+
, it is 
possible that [Ru(bb7)(dppz)]
2+
 either binds more strongly to the membrane (thereby 
increasing the proportion of the complex partitioning into the membrane) or increases the 
permeability of the membrane allowing higher concentrations of the ruthenium complex to 
accumulate in the bacterial cell.  
 
While [Ru(bb7)(dppz)]
2+
 showed significant activity against Gram-negative bacteria, it is 
acknowledged that [Ru(bb7)(dppz)]
2+
 is also more toxic towards eukaryotic cells than the 
parent complex [Ru(phen)2(dppz)]
2+
.  However, [Ru(bb7)(dppz)]
2+
 does exhibit greater 
activity against bacteria than healthy eukaryotic cells.  Furthermore, it is likely that the 
differential between the antimicrobial activity and the toxicity towards eukaryotic cells could 
be increased through the incorporation of bbn ligands that contain a shorter alkyl chain.   
 
Conclusions 
In summary, the new mononuclear dppz-based complex [Ru(bb7)(dppz)]
2+
  
has been synthesised and characterised.  The complex and its parent complex 
[Ru(phen)2(dppz)]
2+
 exhibited high activity against Gram-positive bacteria, but only 
[Ru(bb7)(dppz)]
2+
 showed good activity against Gram-negative species.  Cellular 
accumulation assays demonstrated that [Ru(bb7)(dppz)]
2+
 accumulated in Gram-negative 
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bacteria to the same degree as Gram-positive species.  Assays with DOPG liposomes 
suggested that  [Ru(bb7)(dppz)]
2+
 interacted more strongly with membranes than 
[Ru(phen)2(dppz)]
2+
, which could make the membranes more permeable to the cationic metal 
complexes.  
 
Experimental section 
Materials and methods 
All materials were commercially available and were used without further purification.  
The compounds bb7, dppz, cis-[RuCl2(DMSO)4], cis,cis-[RuCl2(DMSO)2(dppz)], cis-
[Ru(bpy)2Cl2].2H2O and [Ru(phen)2(dppz)]Cl2 were synthesised according to the literature 
methods.
[9,26,38-41]
  Amberlite IRA-402 (chloride form) anion-exchange resin and SP-
Sephadex C-25 cation exchanger was purchased from GE Health Care Bioscience.  
 
Physical measurement 
1
H NMR spectra was recorded on a Varian Advance 400 MHz spectrometer in d6-DMSO. 
Mass spectra (ESI-MS) were recorded using at the RSC Mass Spectrometry Facility at the 
Australian National University (Finngan MAT, USA) and the quoted m/z values are for the 
major peaks in the isotope distribution.  Emission spectra were recorded on a Cary Eclipse 
Fluorescence Spectrophotometer at room temperature.  Microanalyses (C, H, and N) were 
performed at the Campbell Microanalytical Laboratory at the Chemistry Department, 
University of Otago in New Zealand. 
 
Synthesis of [Ru(bb7)(dppz)](PF6)2  
A mixture of cis,cis-[RuCl2(DMSO)2(dppz)] 0.244 g (ca. 0.40 mmol), bb7 (0.213 g, 0.47 
mmol), and ethylene glycol (30 mL) was heated at 130 ¡C under argon for 2 h.  After cooling, 
the resulting solution was diluted with water (ca. 20 mL) and filtered.  The filtrate was loaded 
onto a SP Sephadex C-25 cation-exchange column (3×20 cm).  The desired mononuclear 
complex was eluted with 1.0 M NaCl solution-acetone (5:1, v/v).  Solid KPF6 was added to 
the eluate, resulting in the red precipitate of the mononuclear complex.  The complex was 
extracted into dichloromethane (2 × 30 mL).  The organic layer was washed with small 
amounts of water, then dried over anhydrous Na2SO4.  Filtration, followed by removal of the 
solvent and drying of the residue in vacuo, gave a red microcrystalline solid. Yield: 0.060 g, 
15.3%. Anal. Calcd for C47H42N8F12P2Ru: C, 50.9; H, 3.81; N, 10.1%; Found: C, 51.3; H, 
4.00; N, 10.6%.  ESI-MS (CH3CN): m/z = 965.2 ([M−PF6−]
 +
), 410.1 ([M−2PF6−]
2+
).  
1
H NMR 
(400 MHz, ppm, DMSO-d6): 9.72 (d, J = 8.0 Hz, 2H; dppz 4,7), 8.74 (d, J = 5.2 Hz, 2H; dppz 
2,9), 8.54 (dd, J1 = J2 = 3.2 Hz, 2H; dppz 12,13), 8.33 (s, 2H; bipy 3), 8.19 (m, 2H; bipy 3'; 
dppz 11,14), 7.91 (dd, J1 = J2 = 5.6 Hz, 2H; dppz 3,8), 7.51 (d, J = 5.6 Hz, 2H; bipy 6), 7.43 (d, 
J = 6.0 Hz, 2H; bipy 6'), 7.13 (d, J = 5.2 Hz, 2H; bipy 5), 7.07 (d, J = 5.6 Hz, 2H; bipy 5'), 
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2.86 (m, 2H; CH2 bipy), 2.67 (m, 2H; CH2 bipy), 2.50 (s, 6H; CH3 bipy), 1.67-1.48 (m, 4H; 
CH2 bipy), 0.93-0.79 (m, 6H; 3 × CH2).  UV/Vis [λ/nm (ε/M
-1
 cm
-1
)] (H2O): 439 (19200); 
372 (22300); 357 (22550); 283 (98900).  Luminescence: λex = 439 and λem = 615 nm. 
 
[Ru(bb7)(dppz)](PF6)2 was converted to the chloride salt by stirring in methanol with 
Amberlite IRA-402 (chloride form) anion-exchange resin for 1 h. 
 
Bacterial strains 
Two S. aureus (Gram-positive) isolates {a wild type S. aureus strain (SH 1000) and a clinical 
multidrug-resistant MRSA strain (USA 300 LAC JE2)}, and three Gram-negative E. coli 
isolates {MG 1655, NCTC 12241 (APEC) and ST 131 (UPEC)} and a P. aeruginosa strain 
PAO1 (WT), were used for in vitro MIC and MBC antimicrobial assays. 
 
Lipophilicity (log P) determination 
The measurement of the octanol-water partition coefficients were performed using the Òshake-
flaskÓ method.
[42]
  The chloride salt of the ruthenium complex (0.1 mM) was dissolved in the 
water phase and an equal volume of n-octanol was added.  After saturation of both phases by 
shaking overnight at room temperature, the concentration of the complex in each phase was 
determined spectroscopically at 450 nm.  
 
MIC and MBC determination 
MIC and MBC were measured by using the broth micro-dilution method described in the 
CLSI guidelines and the standard microbiological techniques protocol.
[43] 
 After inoculation 
with different bacteria with different concentrations of ruthenium complexes, the growth rates 
of bacteria were determined by counting colony forming unit (cfu) in each plate.  The final 
concentration of bacterial suspension was 4-8 × 10
5
 cfu/mL and the final concentration range of 
ruthenium complexes tested was between 0.25 and 128 mg/L.  MICs were recorded after 16Ð
18 h at 37 ¡C.  After incubation for another 4 h, MBCs were recorded when the complexes 
produced a 99.9% kill relative to the starting inoculum and the wells with no visible growth 
were taken into colony counting.  
 
Cellular accumulation 
The cellular accumulation of the ruthenium complexes was measured by monitoring the 
luminescence of the ruthenium(II) complexes that remained in the culture supernatant after 
removing the bacteria by centrifugation after incubation for various periods of time.  Bacterial 
inocula in the log phase were adjusted to a cell concentration of 1Ð5 × 10
7
 cfu mL
-1
.  Cell 
culture (24 mL) was placed in a 250 mL conical flask and 75 µL of stock solution (2.56 
mg/mL) of the ruthenium complex was added to give a final concentration of 8 µg/mL.  
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Control flasks containing 50 mL of each bacterial suspension were set up as blank samples to 
obtain luminescence calibration curves for each complex.  Culture flasks and control flasks 
were incubated with shaking at 200 rpm at 37 ¡C for 15, 30, 60, 90 or 120 min.  At each time 
point, 3.3 mL of bacterial suspension were centrifuged (5500 rpm) at 4 ¡C for 10 min.  
Supernatants (3 mL) were carefully transferred to 5 mL tubes and the luminescence of the 
remaining ruthenium complex was measured using a Cary Eclipse Fluorescence 
Spectrophotometer with λex = 488 nm and λem = 640 nm.  Volumes (21, 39, 57, 75 and 93 µL) 
of a stock solution (320 µg mL
-1
) of each complex were added to 3 mL aliquots of the 
supernatant from each control bacterial suspension (untreated with drug) to acquire a 
luminescence-concentration linear correlation chart for calibration. 
 
DNA-binding Experiments 
The DNA-binding experiments were carried out in phosphate-buffered saline (PBS) at 
pH 7.4.  The solution of calf-thymus DNA in PBS buffer gave a ratio of UV absorbance of 
1.8-1.9:1 at 260 and 280 nm, indicating that the DNA was sufficiently free of protein.  The 
concentration of DNA per nucleotide was determined spectroscopically using a molar 
absorption coefficient of 13,300 M
-1 
cm
-1 
per base pair at λabs = 260 nm. 
 
In order to determine the DNA-binding affinities between complexes and DNA, the 
absorption titrations of Ru(II) complexes in PBS buffer were carried out by adding an 
increasing volume of stock DNA solution to the constant concentration (20 µM) of  ruthenium 
complex solution at room temperature.  The complex-DNA solutions were allowed to 
incubate for 5 min before the absorption spectra were recorded.  The intrinsic binding 
constants K to DNA were calculated by a non-linear least-square method using eq. 1:
[35]
  
 
ttfbfa KCsCKbb 2/))/]DNA[2(()/()(
2/122
−−=−− εεεε      (1a) 
                       
sKKCb
t
2/]DNA[1 ++=                             (1b) 
 
where [DNA] is the concentration of DNA in M (nucleotide), εa is the absorption coefficient 
observed for the 
1
MLCT absorption band at a given DNA concentration, εf is the absorption 
coefficient of the free complex without DNA, εb is the absorption coefficient of the complex 
fully bound to DNA.  K is the equilibrium binding constant in M
-1
, Ct is the total metal 
complex concentration and s is the binding site size.  
 
Liposome leakage experiment  
Liposomes were made using 1,2-dioleoylphosphatidylglycerol (DOPG) (sodium salt) 
according to the literature.
[23]
  5(6)-Carboxyfluorescein, disodium salt (CF, Sigma Aldrich, 
Taufkirchen, Germany) was enclosed in the aqueous core of the liposomes.  Liposome release 
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assays using carboxyfluorescein were performed as follows: compound sample (1 µg /mL, 20 
µL), liposomes (10 µL) and buffer {50 mM sodium phosphate, 10 mM NaCl and 1 mM of 
ethylenediaminetetraacetic acid (EDTA); pH 7.4; 170 µL} were incubated.  Fluorescence was 
measured using a Cary Eclipse Fluorescence Spectrophotometer.  Colistin was used as control 
to determine whether the ruthenium complexes can destroy liposomes and 0.01% Triton X-
100 was used to measure complete dye release after incubation with compound for 3 min.  
For carboxyfluorescein λex = 490 nm and λem = 520 nm. 
 
Cytotoxicity assays 
Half-maximal inhibitory concentrations (IC50) of the ruthenium complexes against ACHN, 
HEK-293, HepG2 and L02 cell lines were determined using the CCK-8 cytotoxicity assay 
(Dojindo, Tokyo, Japan) according to the manufacturerÕs protocol.  Cells (3000 per well) 
were seeded in 96-well plates in RPMI-1640 media with 10% FBS overnight.  The cells were 
treated with various concentrations (ranging between 1.56 and 400 µΜ) of the ruthenium 
complexes for 48 h at 37 ¡C with 5% CO2.  Cisplatin served as an evaluation standard.  The 
average values presented are based on at least three independent experiments.  The IC50 
values were determined using GraphPad Prism 6.0.   
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Graphical Abstract 
 
 
 
Activity against Gram-negative bacteria.  According to the WHO, Gram-negative bacteria 
pose a major threat to global health.  To date, ruthenium(II) complexes containing a dppz 
ligand (commonly known as ÒDNA light-switchesÓ) have exhibited poor activity against 
Gram-negative bacteria.  However, incorporation of a tetradentate ligand containing an alkyl 
chain, as shown in Figure, results in a ruthenium(II)-dppz complex that is active against both 
Gram-positive and Gram-negative bacteria.   
 
 
 
 
Keywords:  antimicrobial agents; bioinorganic chemistry; DNA binding; lipophilicity; 
ruthenium(II) complexes  
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